Loading
companiesCompany
Disc Medicine
Disc Medicine is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing DISC-0974 and DISC-3405 in myeloproliferative neoplasms and myelodysplastic syndromes / neoplasms.
Also called: Disc Medicine, Inc
Overview
Disc Medicine is a clinical-stage biopharmaceutical company developing medicines for haematological diseases; its pipeline includes bitopertin, DISC-0974 and DISC-3405. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06985147 (phase 2, A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)) and NCT05320198 (phase 1/2, Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syn...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Similar pages
- TargetCDA
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TargetSLX4
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TargetDDX41
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TrialA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TargetPOLA2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TargetPOLD2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TargetPOLD3
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TargetPOLD4
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).